Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocugen, Inc. (NASDAQ: OCGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding Ocugen’s development plans in gene therapies for blindness diseases, its financial condition, and key corporate actions.
Ocugen uses Form 8‑K current reports to announce material events, including exclusive licensing agreements, registered direct offerings of common stock and warrants, litigation developments, and Nasdaq listing compliance updates. For example, recent 8‑K filings describe an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, a securities purchase agreement for a registered direct offering, and court decisions related to a securities class action lawsuit.
Periodic reports such as Form 10‑Q and Form 10‑K (when available) provide more comprehensive information on Ocugen’s financial results, operating expenses, and risk factors. In a recent earnings-related press release furnished on Form 8‑K, the company detailed revenue from collaborative arrangements, research and development expenses, general and administrative expenses, and net loss figures, along with commentary on cash runway and financing plans.
Investors can also review filings that discuss executive compensation and equity awards, such as performance restricted stock units granted to senior leadership, and agreements related to licensing, supply, and regional commercialization of products like OCU400. These filings help clarify how management is incentivized and how Ocugen structures partnerships around its modifier gene therapy platform.
On Stock Titan, Ocugen’s SEC filings are updated in near real time from the EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections on clinical programs, licensing terms, capital raises, and governance matters, and make it easier to locate items such as quarterly results, material agreements, and other disclosures relevant to OCGN stock.
Ocugen, Inc. entered into an Exclusive License Agreement with Kwangdong Pharmaceutical, granting Kwangdong exclusive rights in the Republic of Korea to develop, register, commercialize, and sell OCU400, Ocugen’s modifier gene therapy for retinitis pigmentosa. Kwangdong will also use a trademark selected by Ocugen for OCU400 in this indication.
Ocugen will receive a $1 million upfront license fee, up to $6.5 million in regulatory and development milestone payments, and additional sales milestone payments of $1.5 million for every $15 million of sales in Korea. Ocugen is also entitled to a 25% royalty on Kwangdong’s net sales of OCU400 and will manufacture commercial supply under a separate supply agreement.
The license will remain in force until the latest of 20 years after the first commercial sale in Korea, expiry of relevant patent claims, or expiry of regulatory exclusivity for OCU400 in the territory, with customary termination rights for material breach or certain insolvency events.
Ocugen, Inc. entered into a Subscription Agreement with Carisma Therapeutics Inc. under which Ocugen agreed to invest $5.0 million in Carisma common stock in a private placement. This investment is part of an anticipated concurrent financing of at least $25.0 million tied to the planned merger among Ocugen’s subsidiary OrthoCellix, Carisma and a Ocugen merger subsidiary. The price per Carisma share for Ocugen’s investment will be calculated by dividing the “Aggregate Valuation” by the “Post-Closing Parent Shares,” as defined in the merger agreement.
Ocugen will automatically receive any more favorable rights granted to other investors in the concurrent investment, subject to specified exceptions. At the closing of the concurrent investment, Carisma intends to enter a registration rights agreement covering resale of certain shares, including the Carisma shares purchased by Ocugen. Closing of both the Carisma investment and the broader transactions remains subject to customary conditions and numerous risks and uncertainties described by the companies.
Ocugen, Inc. entered into agreements to sell 20,000,000 shares of common stock at $1.00 per share and accompanying warrants to purchase up to 20,000,000 shares. The financing is structured as a registered direct offering made under the company's effective Form S-3 shelf registration and is expected to generate approximately $20.0 million in gross proceeds before fees and expenses.
The Warrants carry an exercise price of $1.50, are exercisable immediately, and expire two years after issuance; they are callable by the company if the volume-weighted average price exceeds $2.50 for five of a trailing 30 trading day period. The investor agreed to a 90-day lock-up on resale of the securities. Noble Capital Markets is acting as sole placement agent and will receive a 5.5% cash fee plus reimbursement of up to $65,000 of expenses.
Ocugen is conducting a registered direct offering to sell 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 additional shares, at a combined price of $1.00 per share plus warrant. The company will receive approximately $18.9 million of net proceeds after a 5.5% placement-agent fee; investors would incur immediate dilution of $0.926 per share versus the offering price. Each warrant is exercisable for one share at $1.50, exercisable immediately and expiring two years after issuance; the warrants are not listed and have limited liquidity.
Separately, Ocugen highlights clinical and corporate milestones: positive two-year Phase 1/2 OCU400 data and EMA ATMP positive opinion, ongoing Phase 3 enrollment for OCU400, initiation and regulatory clearance activity for OCU410ST and OCU200, and a planned merger of the NeoCart business with Carisma (Ocugen to invest at least $5.0 million and is estimated to own >50% of the combined company if the merger closes). The company states proceeds should fund operations into Q2 2026 (or into Q1 2027 if warrants are fully exercised).